[
    [
        {
            "time": "2021-06-08",
            "original_text": "Should I Buy Eli Lilly and Company (LLY)?",
            "features": {
                "keywords": [
                    "Eli Lilly",
                    "buy",
                    "LLY"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Should I Buy Eli Lilly and Company (LLY)?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-08",
            "original_text": "Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO",
            "features": {
                "keywords": [
                    "Biogen",
                    "Alzheimer’s",
                    "drug",
                    "approval",
                    "surprising",
                    "Eli Lilly",
                    "CEO"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "healthcare"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "Biogen Alzheimer’s drug approval was 'surprising for a lot of people': Eli Lilly CEO",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-06-08",
            "original_text": "FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO",
            "features": {
                "keywords": [
                    "FDA",
                    "shifting",
                    "bar",
                    "approval",
                    "Alzheimer’s",
                    "drug",
                    "Eli Lilly",
                    "CEO"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals",
                    "regulatory"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 9,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]